Transcatheter septal ablation in hypertrophic obstructive cardiomyopathy: a technical guide and review of published...

Area of Science:

• Cardiology
• Interventional Cardiology
• Cardiac Surgery

Background:

• Hypertrophic obstructive cardiomyopathy (HOCM) causes intraventricular obstruction, impacting symptomatic patients.
• Optimal medical therapy is insufficient for some HOCM patients, necessitating septal reduction strategies.
• Surgical septal myectomy and transcatheter alcohol septal ablation (ASA) are primary interventions for gradient reduction.

Purpose of the Study:

• To evaluate the efficacy and safety of transcatheter alcohol septal ablation (ASA) for symptomatic HOCM.
• To compare ASA with surgical septal myectomy as a treatment for intraventricular obstruction.
• To highlight the importance of patient selection and technical details in ASA outcomes.

Main Methods:

• ASA involves occluding a septal branch artery supplying the hypertrophied septum with ethanol injection.
• Echocardiographic contrast guidance is crucial for accurate septal branch selection and procedure optimization.
• Patient selection is based on significant intraventricular gradient and symptoms unresponsive to medical therapy.

Main Results:

• ASA is a highly effective and safe method for reducing intraventricular obstruction in HOCM.
• Long-term results from high-volume centers demonstrate excellent survival rates, comparable to the general population.
• ASA has become a preferred alternative, often outnumbering surgical septal myectomy.

Conclusions:

• Transcatheter alcohol septal ablation is an established, effective, and safe treatment for HOCM.
• Optimal outcomes depend on careful patient selection and precise procedural technique within specialized centers.
• A heart-team approach is recommended for personalized treatment decisions in HOCM management.